Evidence map›Paper›PMID 25638805›Full record

ArticleHaematologica2015

Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study).

Morena Caira, Anna Candoni, Luisa Verga, Alessandro Busca, Mario Delia, Annamaria Nosari, Cecilia Caramatti, Carlo Castagnola, Chiara Cattaneo, Rosa Fanci and 35 more

2 registry-linked trialsOpen access · goldAbstract readComparative StudyMulticenter Study
In one paragraph

Article in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01315925 unknown statusnot on this map

SEIFEM 2010: Epidemiological Survey on Possible Pre-Hospital Risk Factors for Developing Invasive Fungal Infections in Patients Affected by Acute Myeloid Leukemia

TypeobservationalSponsorCatholic University of the Sacred HeartRan2010Enrolled1,000ConditionsAcute Myeloid Leukemia, Aspergillosis, Candidiasis, Mycoses
NCT02451592 completednot on this map

SEIFEM 2015: Fungemia in Hematologic Malignancies

TypeobservationalSponsorSorveglianza Epidemiologica Infezioni Fungine Emopatie MaligneRan2011 to 2016Enrolled300ConditionsAcute Leukemia, Chronic Leukemia, Multiple Myeloma, Lymphoma
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 79 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Managing Invasive Fungal Infections During Allogeneic Hematopoietic Transplantation: A 2025 Update.Mediterranean journal of hematology and infectious diseases · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Liposomal amphotericin B-the present.The Journal of antimicrobial chemotherapy · 2022
    Article
  11. DisseminatedJournal of fungi (Basel, Switzerland) · 2021
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. A Prospective Observational Multi-institutional Study on Invasive Fungal Infections Following Chemotherapy for Acute Myeloid Leukemia (MISFIC Study): A Real World Scenario from India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2020
    Article
  18. Review
  19. High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors at 20 institutions in 1 country.

Morena CairaIstituto di Ematologia, Università Cattolica del Sacro Cuore, Roma morenacaira@yahoo.it.
Anna CandoniClinica Ematologica, Azienda Ospedaliero Universitaria di Udine.
Luisa VergaUnità di Ematologia, Università Milano Bicocca, Ospedale S.Gerardo, Monza.
Alessandro BuscaS.C. Ematologia, AO Città della Salute e della Scienza, Torino.
Mario DeliaHematology and BMT Unit, Department of Emergency and Organ Transplantation, University of Bari, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari.
Annamaria NosariDivisione di Ematologia e Centro Trapianti Midollo, Ospedale Niguarda Ca' Granda, Milan.
Cecilia CaramattiSezione di Ematologia, Università di Parma.
Carlo CastagnolaDipartimento Onco-Ematologico Fondazione ICRRS Policlinico San Matteo, Pavia.
Chiara CattaneoDivisione di Ematologia, Spedali Civili di Brescia.
Rosa FanciUnità Funzionale di Ematologia, Azienda Ospedaliero-Universitaria Careggi e Università di Firenze.
Anna ChierichiniUOC Ematologia, Azienda Ospedaliera S.Giovanni Addolorata, Roma.
Lorella MelilloUnità di Ematologia, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo.
Maria Enza MitraDivisione di Ematologia e TMO, Policlinico di Palermo.
Marco PicardiAzienda Ospedaliera Universitaria Federico II Napoli, Dipartimento di Medicina Clinica e Chirurgia.
Leonardo PotenzaSezione di Ematologia, Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università di Modena e Reggio Emilia.
Prassede SalutariDipartimento di Ematologia Clinica, Ospedale Santo Spirito, Pescara.
Nicola VianelliIstituto di Ematologia ed Oncologia Clinica "Lorenzo e Ariosto Serágnoli", Ospedale S.Orsola-Malpighi, Università di Bologna.
Luca FacchiniDivisione di Ematologia, Arciospedale S.Maria Nuova, Reggio Emilia.
Monica CesariniIstituto di Ematologia, Università Cattolica del Sacro Cuore, Roma.
Maria Rosaria De PaolisDipartimento di Ematologia, Ospedale di Lecce.
Roberta Di BlasiIstituto di Ematologia, Università Cattolica del Sacro Cuore, Roma.
Francesca FarinaUnità di Ematologia, Università Milano Bicocca, Ospedale S.Gerardo, Monza.
Adriano VendittiEmatologia, Dipartimento di Biomedicina e Prevenzione, Università Tor Vergata, Roma.
Antonella FerrariOspedale S.Andrea, Roma.
Mariagrazia GarziaDivisione di Ematologia, Ospedale San Camillo, Roma.
Cristina GasbarrinoDivisione di Ematologia, Università Cattolica del S.Cuore, Campobasso.
Rosangela InvernizziDipartimento di Medicina Interna, Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia.
Federica LessiEmatologia ed Immunologia Clinica, Dipartimento di Medicina, Universita' di Padova.
Annunziata MannaUnità Complessa di Oncoematologia, Ospedale di La Spezia.
Bruno MartinoDivisione di Ematologia, Azienda Ospedaliera "Bianchi Melacrino Morelli", Reggio Calabria.
Gianpaolo NadaliUOC Ematologia, Azienda Ospedaliera Universitaria Integrata di Verona.
Massimo OffidaniClinica di Ematologia, Università di Ancona.
Laura ParisDivisione di Ematologia e Centro Trapianti Midollo, Ospedale Niguarda Ca' Granda, Milan.
Vincenzo PavoneClinica di Ematologia, Ospedale di Tricase.
Giuseppe RossiDivisione di Ematologia, Spedali Civili di Brescia.
Antonio SpadeaUnità di Ematologia, Istituti Fisioterapici Ospitalieri, Roma.
Giorgina SpecchiaHematology and BMT Unit, Department of Emergency and Organ Transplantation, University of Bari, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari.
Enrico Maria TrecarichiIstituto di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma.
Adriana VaccaEmatologia-CTMO" Ospedale Roberto Binaghi Cagliari.
Simone CesaroEmato-Oncologia Pediatrica, Azienda Ospedaliera Universitaria Integrata, Verona.
Vincenzo PerrielloIstituto di Ematologia, Ospedale S. Maria della Misericordia, Università di Perugia, Italy.
Franco AversaSezione di Ematologia, Università di Parma.
Mario TumbarelloIstituto di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma.
Livio PaganoIstituto di Ematologia, Università Cattolica del Sacro Cuore, Roma.
SEIFEM Group (Sorveglianza Epidemiologica Infezioni Fungine in Emopatie Maligne)
Università Cattolica del Sacro Cuore · ITAzienda Ospedaliera Universitaria Integrata Verona · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITIstituto di Ematologia di Bologna · ITUniversity of Bari Aldo Moro · ITUniversity of Milano-Bicocca · ITAzienda ospedaliera "Bianchi-Melacrino-Morelli" · ITAzienda Ospedaliera San Giovanni Addolorata · ITAzienda Ospedaliera Sant'Andrea · ITAzienda Ospedaliera S.Maria · ITAzienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo · ITAzienda Ospedaliero-Universitaria Careggi · ITCasa Sollievo della Sofferenza · ITFederico II University Hospital · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituti Fisioterapici Ospitalieri · ITIstituto Nazionale di Fisica Nucleare, Sezione di Lecce · ITOspedale di Cattinara · ITOspedale di Santo Spirito · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Correct definition of the level of risk of invasive fungal infections is the first step in improving the targeting of preventive strategies. We investigated the potential relationship between pre-hospitalization exposure to sources of fungi and the development of invasive fungal infections in adult patients with newly diagnosed acute myeloid leukemia after their first course of chemotherapy. From January 2010 to April 2012, all consecutive acute myeloid leukemia patients in 33 Italian centers were prospectively registered. Upon first admission, information about possible pre-chemotherapy risk factors and environmental exposure was collected. We recorded data regarding comorbid conditions, employment, hygienic habits, working and living environment, personal habits, hobbies, and pets. All invasive fungal infections occurring within 30 days after the first course of chemotherapy were recorded. Of the 1,192 patients enrolled in this study, 881 received intensive chemotherapy and were included in the present analysis. Of these, 214 developed an invasive fungal infection, including 77 proven/probable cases (8.7%). Of these 77 cases, 54 were proven/probable invasive mold infections (6.1%) and 23 were proven yeast infections (2.6%). Upon univariate analysis, a significant association was found between invasive mold infections and age, performance status, diabetes, chronic obstructive pulmonary disease, smoking, cocaine use, job, hobbies, and a recent house renovation. Higher body weight resulted in a reduced risk of invasive mold infections. Multivariate analysis confirmed the role of performance status, job, body weight, chronic obstructive pulmonary disease, and house renovation. In conclusion, several hospital-independent variables could potentially influence the onset of invasive mold infections in patients with acute myeloid leukemia. Investigation of these factors upon first admission may help to define a patient's risk category and improve targeted prophylactic strategies. (Clinicaltrial.gov: NCT01315925)

Indexed as

Immunocompromised HostAdultAgedAntifungal AgentsAntineoplastic Combined Chemotherapy ProtocolsCase-Control StudiesFemaleFollow-Up StudiesHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMycosesNeoplasm StagingPrognosisProspective StudiesAntifungal Agents

Identifiers

PMID25638805
PMCPMC4803126
OpenAlexW2144322736

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.